GlassScriptPhysician profile
Michael L Scharf
NPI 1417998956
$12,434.81
in general payments reported to CMS, 2019-2025
15 companies · $116 in 2025
The $116 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,234 · 2021: $60.25 · 2022: $361 · 2023: $7,543 · 2024: $121 · 2025: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,370 · Travel and Lodging: $1,802 · Food and Beverage: $530 · Education: $77.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,370.00 |
| Travel and Lodging | $1,802.43 |
| Food and Beverage | $529.95 |
| Education | $77.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $9,007.92 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,440.00 | 2023 | |
| Glaxosmithkline, LLC. | $232.68 | 2022-2025 | Nucala, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $173.30 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $142.11 | 2021-2024 | Opsumit, Uptravi |
| Stryker Corporation | $135.82 | 2022 | |
| Merck Sharp & Dohme LLC | $77.10 | 2025 | Winrevair |
| Haemonetics Corporation | $73.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.17 | 2023-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $47.19 | 2022-2024 | Arikayce |
| Ethicon US, LLC | $27.99 | 2023 | Dermabond, Stratafix, Surgiflo Hemostatic Matrix |
| Astrazeneca Pharmaceuticals LP | $13.83 | 2024 | |
| Electromed, INC. | $12.91 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Scharf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.